- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01280903
Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension (STAR)
Promoting Physical Activity in Older Adults With Comorbidity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15261
- University of Pittsburgh School of Nursing
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 50 years or older.
- Is community dwelling.
- Has osteoarthritis of the knee.
- Has hypertension for which monotherapy or combination pharmacological treatment is prescribed.
- Able to complete a behavioral run-in consisting of completing questionnaires, using a 7-day electronic-diary, and wearing an ActiGraph accelerometer at the waist for 7 days.
- Has written permission to participate from the physician.
Exclusion Criteria:
- Reports currently doing lower extremity exercise => 2 times/week.
- Reports currently fitness walking => 90 minutes/week.
- Incapable of managing their own treatment regimen.
- Does not have, or cannot use, a telephone or is unwilling to provide a telephone number.
- Has received cortisone or Synvisc injections in the knee, angioplasty, stents, or a pacemaker in the past 6 months.
- Reports unstable cardiovascular, pulmonary, or metabolic disease or signs and symptoms suggestive of cardiovascular, pulmonary, or metabolic disease that restrict activity.
- Has resting systolic blood pressure => 160 mm Hg or diastolic blood pressure => 100 mm Hg.
- Reports other conditions, such as osteoarthritis of the hip, spinal stenosis, inflammatory arthritis, foot drop, diabetes treated with insulin, or diabetic complications that may affect performance of lower extremity exercise and participation in fitness walking.
- Reports current knee conditions, such as meniscus tears and knee ligament ruptures.
- Reports major depression that may impact the ability to fully participate in this study.
- Is scheduled to undergo a major surgical procedure in the next 13 months.
- Is concurrently participating in a drug or psychoeducational trial that may confound, or be confounded by, participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: STAR Intervention
Staying Active with Arthritis Intervention
|
The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions.
There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23.
During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
|
|
Placebo Comparator: Attention-Control
Senior Health Information Intervention
|
Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse.
There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23.
Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression).
During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance of Lower Extremity Exercise at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the electronic-diary in terms of the total volume of lower extremity exercise (i.e., the number of days the participant reports completing a lower extremity exercise session and the total number of lower extremity exercises per day performed [repetitions x sets] over a 7-day period).
|
At the end of the 6-month intervention period (week 25)
|
|
Participation in Fitness Walking at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the ActiGraph accelerometer in terms of mean daily activity minutes of none to very low, light, and moderate-to-vigorous activity counts summarized over a 7-day period.
|
At the end of the 6-month intervention period (week 25)
|
|
Objective Functional Status by the 6-minute Walk at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the 6-minute walk (yards) as part of the performance-based functional status assessment.
|
At the end of the 6-month intervention period (week 25)
|
|
Objective Functional Status by the Short Physical Performance Battery at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Short Physical Performance Battery (total scale score) as part of the performance-based functional status assessment; subscale scores are summed for a total scale score; the scale score range is 0-13; higher scores are better.
|
At the end of the 6-month intervention period (week 25)
|
|
Systolic Blood Pressure at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
|
At the end of the 6-month intervention period (week 25)
|
|
Diastolic Blood Pressure at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
|
At the end of the 6-month intervention period (week 25)
|
|
Performance of Lower Extremity Exercise at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the electronic-diary in terms of the total volume of lower extremity exercise (i.e., the number of days the subject reports completing a lower extremity exercise session and the total number of lower extremity exercises per day performed [repetitions x sets] over a 7-day period).
|
6 months after the intervention period ends (week 52)
|
|
Participation in Fitness Walking at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the ActiGraph accelerometer in terms of mean daily activity minutes of none to very low, light, and moderate-to-vigorous activity counts summarized over a 7-day period.
|
6 months after the intervention period ends (week 52)
|
|
Objective Functional Status by the 6-minute Walk at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the 6-minute walk (yards) as part of the performance-based functional status assessment.
|
6 months after the intervention period ends (week 52)
|
|
Objective Functional Status by the Short Physical Performance Battery at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Short Physical Performance Battery (total scale score) as part of the performance-based functional status assessment; subscale scores are summed for a total scale score; the scale score range is 0-13; higher scores are better.
|
6 months after the intervention period ends (week 52)
|
|
Systolic Blood Pressure at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
|
6 months after the intervention period ends (week 52)
|
|
Diastolic Blood Pressure at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
|
6 months after the intervention period ends (week 52)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Functional Status at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Physical Function subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-68; lower scores are better.
|
At the end of the 6-month intervention period (week 25)
|
|
Quadriceps Strength at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the MicroFET2 hand-held dynamometer in terms of mean maximum pounds over two trials.
|
At the end of the 6-month intervention period (week 25)
|
|
Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Pain subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-20; lower scores are better.
|
At the end of the 6-month intervention period (week 25)
|
|
Pain by the Bodily Pain Subscale of the Short Form-36v2 at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Bodily Pain subscale of the Short Form-36v2; the subscale score range is 0-100; higher scores are better.
|
At the end of the 6-month intervention period (week 25)
|
|
Fatigue at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Brief Fatigue Inventory, which assesses fatigue severity; the scale score range is 0-10; lower scores are better.
|
At the end of the 6-month intervention period (week 25)
|
|
Health-Related Quality of Life at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Short Form-36v2 in terms of the following: Mental Component: this summary scale is composed of eight subscale scores primarily derived from the mental health, role functioning-emotional, and social functioning scores; the scale score range is 0-100; higher scores are better Physical Component: this summary scale is composed of eight subscale scores primarily derived from the physical functioning, role functioning-physical, and bodily pain scores; the scale score range is 0-100; higher scores are better |
At the end of the 6-month intervention period (week 25)
|
|
Self-Efficacy at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Self-Efficacy Scale in terms of the following: Exercise Barriers Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better Exercise Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better |
At the end of the 6-month intervention period (week 25)
|
|
Arthritis Self-Efficacy at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Arthritis Self-Efficacy Scale in terms of the following: Pain subscale: the subscale score range is 10-100; higher scores are better Function subscale: the subscale score range is 10-100; higher scores are better Other Symptoms subscale: the subscale score range is 10-100; higher scores are better |
At the end of the 6-month intervention period (week 25)
|
|
Outcome Expectancy at 25 Weeks
Time Frame: At the end of the 6-month intervention period (week 25)
|
Measured by the Perceived Therapeutic Efficacy Scale in terms of the following: Exercise and Arthritis: the scale score range is 0-100; higher scores are better Exercise and Hypertension: the scale score range is 0-100; higher scores are better |
At the end of the 6-month intervention period (week 25)
|
|
Subjective Functional Status at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Physical Function subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-68; lower scores are better.
|
6 months after the intervention period ends (week 52)
|
|
Quadriceps Strength at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the MicroFET2 hand-held dynamometer in terms of mean maximum pounds over two trials.
|
6 months after the intervention period ends (week 52)
|
|
Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Pain subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-20; lower scores are better.
|
6 months after the intervention period ends (week 52)
|
|
Pain by the Bodily Pain Subscale of the Short Form-36v2 at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Bodily Pain subscale of the Short Form-36v2; the subscale score range is 0-100; higher scores are better.
|
6 months after the intervention period ends (week 52)
|
|
Fatigue at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Brief Fatigue Inventory, which assesses fatigue severity; the scale score range is 0-10; lower scores are better.
|
6 months after the intervention period ends (week 52)
|
|
Health-Related Quality of Life at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Short Form-36v2 in terms of the following: Mental Component: this summary scale is composed of eight subscale scores primarily derived from the mental health, role functioning-emotional, and social functioning scores; the scale score range is 0-100; higher scores are better Physical Component: this summary scale is composed of eight subscale scores primarily derived from the physical functioning, role functioning-physical, and bodily pain scores; the scale score range is 0-100; higher scores are better |
6 months after the intervention period ends (week 52)
|
|
Self-Efficacy at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Self-Efficacy Scale in terms of the following: Exercise Barriers Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better Exercise Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better |
6 months after the intervention period ends (week 52)
|
|
Arthritis Self-Efficacy at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Arthritis Self-Efficacy Scale in terms of the following: Pain subscale: the subscale score range is 10-100; higher scores are better Function subscale: the subscale score range is 10-100; higher scores are better Other Symptoms subscale: the subscale score range is 10-100; higher scores are better |
6 months after the intervention period ends (week 52)
|
|
Outcome Expectancy at 52 Weeks
Time Frame: 6 months after the intervention period ends (week 52)
|
Measured by the Perceived Therapeutic Efficacy Scale in terms of the following: Exercise and Arthritis: the scale score range is 0-100; higher scores are better Exercise and Hypertension: the scale score range is 0-100; higher scores are better |
6 months after the intervention period ends (week 52)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth A. Schlenk, PhD, RN, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO09110029
- R01NR010904-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on STAR Intervention
-
Martha TillsonNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
University of California, San FranciscoSan Francisco Department of Public Health; San Francisco General Hospital; Sonoma...CompletedType 2 Diabetes Mellitus | Gestational Diabetes MellitusUnited States
-
University GhentResearch Foundation Flanders; Agentschap Zorg en Gezondheid, Belgium; Vlaams...CompletedDepressive Symptoms | Well-being | Life Style, Healthy | ResilienceBelgium
-
UMC UtrechtDutch Heart FoundationNot yet recruitingHeart Failure NYHA Class II | Heart Failure NYHA Class III
-
University of ValenciaNot yet recruitingClimacteric Women | Nonspecific Cervical Pain
-
Boston University Charles River CampusCompletedSensory Processing DisorderUnited States
-
Children's Hospital of Fudan UniversityRecruitingAutism Spectrum Disorder | TherapyChina
-
University Hospital Inselspital, BerneCompletedChronic Pelvic Pain SyndromeSwitzerland
-
University of WashingtonNational Institute on Aging (NIA); Kaiser PermanenteCompletedBehavioral Symptoms | Dementia | Alzheimer Disease | Caregiver BurdenUnited States